Literature DB >> 16173915

Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) transcriptional regulation by Oct-1 in human endothelial cells: implications for atherosclerosis.

Jiawei Chen1, Yong Liu, Hongmei Liu, Paul L Hermonat, Jawahar L Mehta.   

Abstract

LOX-1, a receptor for ox-LDL (oxidized low-density lipoprotein), has recently been determined to play a critical role in the progression of atherosclerosis. LOX-1 expression (mRNA and protein) has been shown to be up-regulated by pro-atherogenic stimuli, such as ox-LDL and Ang II (angiotensin II). However, the molecular mechanisms of these up-regulations are unclear. In the present study, we explored LOX-1 transcriptional promoter activation in response to ox-LDL and Ang II. Under basal states, LOX-1 core promoter (LOX-1 -35/+36) was found to be sufficient for its basal activity in HCAECs (human coronary artery endothelial cells). More importantly, we found that ox-LDL (60 microg/ml for 24 h) induced LOX-1 promoter activity significantly and that a 105 bp fragment (between nt -1599 and -1494) was required for this activation. Within this 106 bp fragment, there is a potential binding motif for the transcription factor Oct-1 (octamer-1). By electrophoretic mobility-shift assay, we observed the activation of Oct-1 by ox-LDL. The critical role of Oct-1 in ox-LDL-induced LOX-1 promoter activation was further confirmed by mutagenesis assay. For comparison, we also examined LOX-1 promoter activation in response to Ang II (1 micromol/l for 24 h). Interestingly, another promoter region, between nt -2336 and -1990, was required for Ang II-induced LOX-1 promoter activation. In conclusion, the present study strongly suggests that ox-LDL, by activating Oct-1, induces LOX-1 promoter activation. Furthermore, this study suggests that while ox-LDL and Ang II both induce LOX-1 expression in HCAECs, the underlying mechanisms of promoter activation are different from each other.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16173915      PMCID: PMC1383684          DOI: 10.1042/BJ20050845

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  31 in total

1.  Upregulation of endothelial receptor for oxidized LDL (LOX-1) by oxidized LDL and implications in apoptosis of human coronary artery endothelial cells: evidence from use of antisense LOX-1 mRNA and chemical inhibitors.

Authors:  D Li; J L Mehta
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-04       Impact factor: 8.311

2.  Inhibition of LOX-1 by statins may relate to upregulation of eNOS.

Authors:  J L Mehta; D Y Li; H J Chen; J Joseph; F Romeo
Journal:  Biochem Biophys Res Commun       Date:  2001-12-14       Impact factor: 3.575

3.  Upregulation of LOX-1 expression in aorta of hypercholesterolemic rabbits: modulation by losartan.

Authors:  H Chen; D Li; T Sawamura; K Inoue; J L Mehta
Journal:  Biochem Biophys Res Commun       Date:  2000-10-05       Impact factor: 3.575

4.  Statins modulate oxidized low-density lipoprotein-mediated adhesion molecule expression in human coronary artery endothelial cells: role of LOX-1.

Authors:  Dayuan Li; Hongjiang Chen; Francesco Romeo; Tatsuya Sawamura; Tom Saldeen; Jawahar L Mehta
Journal:  J Pharmacol Exp Ther       Date:  2002-08       Impact factor: 4.030

5.  Cross-talk between dyslipidemia and renin-angiotensin system and the role of LOX-1 and MAPK in atherogenesis studies with the combined use of rosuvastatin and candesartan.

Authors:  Jiawei Chen; Dayuan Li; Robert Schaefer; Jawahar L Mehta
Journal:  Atherosclerosis       Date:  2005-07-06       Impact factor: 5.162

6.  Activation of JAK2 by the oxidative stress generated with oxidized low-density lipoprotein.

Authors:  C Mazière; M A Conte; J C Mazière
Journal:  Free Radic Biol Med       Date:  2001-12-01       Impact factor: 7.376

7.  Oxidized LDL upregulates angiotensin II type 1 receptor expression in cultured human coronary artery endothelial cells: the potential role of transcription factor NF-kappaB.

Authors:  D Li; T Saldeen; F Romeo; J L Mehta
Journal:  Circulation       Date:  2000-10-17       Impact factor: 29.690

8.  3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase the binding activity and nuclear level of Oct-1 in mononuclear cells.

Authors:  Mónica Ortego; Almudena Gómez Hernández; Carmen Bustos; Luis M Blanco-Colio; Miguel Angel Hernández-Presa; Jose Tuñón; Jesús Egido
Journal:  Eur J Pharmacol       Date:  2002-07-19       Impact factor: 4.432

9.  LOX-1 mediates oxidized low-density lipoprotein-induced expression of matrix metalloproteinases in human coronary artery endothelial cells.

Authors:  Dayuan Li; Ling Liu; Hongjiang Chen; Tatsuya Sawamura; Subramanian Ranganathan; Jawahar L Mehta
Journal:  Circulation       Date:  2003-02-04       Impact factor: 29.690

10.  LOX-1, an oxidized LDL endothelial receptor, induces CD40/CD40L signaling in human coronary artery endothelial cells.

Authors:  Dayuan Li; Ling Liu; Hongjiang Chen; Tatsuya Sawamura; Jawahar L Mehta
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-03-13       Impact factor: 8.311

View more
  10 in total

Review 1.  Hyperlipidemia: a new therapeutic target for diabetic neuropathy.

Authors:  Andrea M Vincent; Lucy M Hinder; Rodica Pop-Busui; Eva L Feldman
Journal:  J Peripher Nerv Syst       Date:  2009-12       Impact factor: 3.494

Review 2.  Upregulated LOX-1 Receptor: Key Player of the Pathogenesis of Atherosclerosis.

Authors:  Sanjiv Singh; Avtar Singh Gautam
Journal:  Curr Atheroscler Rep       Date:  2019-07-27       Impact factor: 5.113

3.  Curcumin eliminates oxidized LDL roles in activating hepatic stellate cells by suppressing gene expression of lectin-like oxidized LDL receptor-1.

Authors:  Qiaohua Kang; Anping Chen
Journal:  Lab Invest       Date:  2009-09-07       Impact factor: 5.662

4.  APE1 inhibits foam cell formation from macrophages via LOX1 suppression.

Authors:  Zhaohui Hu; Bo Hui; Xuwei Hou; Ruhui Liu; Sergiy Sukhanov; Xiaohong Liu
Journal:  Am J Transl Res       Date:  2020-10-15       Impact factor: 4.060

Review 5.  LOX-1 in atherosclerosis: biological functions and pharmacological modifiers.

Authors:  Suowen Xu; Sayoko Ogura; Jiawei Chen; Peter J Little; Joel Moss; Peiqing Liu
Journal:  Cell Mol Life Sci       Date:  2012-11-03       Impact factor: 9.261

Review 6.  Atherosclerosis: integration of its pathogenesis as a self-perpetuating propagating inflammation: a review.

Authors:  Robin N Poston
Journal:  Cardiovasc Endocrinol Metab       Date:  2019-05-15

Review 7.  Proteolytic Regulation of the Lectin-Like Oxidized Lipoprotein Receptor LOX-1.

Authors:  Torben Mentrup; Florencia Cabrera-Cabrera; Bernd Schröder
Journal:  Front Cardiovasc Med       Date:  2021-01-20

Review 8.  LOX-1, OxLDL, and atherosclerosis.

Authors:  Angela Pirillo; Giuseppe Danilo Norata; Alberico Luigi Catapano
Journal:  Mediators Inflamm       Date:  2013-07-10       Impact factor: 4.711

9.  Comparison of efficacy of the disease-specific LOX1- and constitutive cytomegalovirus-promoters in expressing interleukin 10 through adeno-associated virus 2/8 delivery in atherosclerotic mice.

Authors:  Hongqing Zhu; Maohua Cao; Leonardo Mirandola; Jose A Figueroa; Everardo Cobos; Maurizio Chiriva-Internati; Paul L Hermonat
Journal:  PLoS One       Date:  2014-04-15       Impact factor: 3.240

10.  CKIP-1 limits foam cell formation and inhibits atherosclerosis by promoting degradation of Oct-1 by REGγ.

Authors:  Jiao Fan; Lifeng Liu; Qingyan Liu; Yu Cui; Binwei Yao; Minghua Zhang; Yabing Gao; Yesheng Fu; Hongmiao Dai; Jingkun Pan; Ya Qiu; Cui Hua Liu; Fuchu He; Yu Wang; Lingqiang Zhang
Journal:  Nat Commun       Date:  2019-01-25       Impact factor: 14.919

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.